Page last updated: 2024-12-07
4-methylumbelliferyl iduronide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
4-methylumbelliferyl iduronide: fluorogenic substrate for (alpha-L)-iduronidase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 128746 |
| SCHEMBL ID | 308321 |
| MeSH ID | M0069736 |
Synonyms (22)
| Synonym |
|---|
| 4-methylumbelliferyl iduronide |
| 66966-09-4 |
| (2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-(4-methyl-2-oxochromen-7-yl)oxyoxane-2-carboxylic acid |
| (2s,3s,4s,5r,6s)-3,4,5-trihydroxy-6-(4-methyl-2-oxochromen-7-yl)oxyoxane-2-carboxylic acid |
| 4-methylumbelliferyl-alpha-l-iduronide |
| 4-methyl-2-oxo-2h-1-benzopyran-7-yl alpha-l-ido-pyranosiduronic acid |
| einecs 266-527-5 |
| alpha-l-idopyranosiduronic acid, 4-methyl-2-oxo-2h-1-benzopyran-7-yl |
| 4-methylumbelliferyl alpha-l-iduronide (free acid) |
| SCHEMBL308321 |
| (2~{r},3~{s},4~{s},5~{r},6~{s})-6-(4-methyl-2-oxidanylidene-chromen-7-yl)oxy-3,4,5-tris(oxidanyl)oxane-2-carboxylic acid |
| 8u8 , |
| 4-methyl-2-oxo-2h-1-benzopyran-7-yl hexopyranosiduronic acid |
| DTXSID10985697 |
| 4-methylumbelliferyl |a-l-iduronide |
| 4-methylumbelliferyl alpha -l-iduronide (free acid) |
| 4mu alpha-l-iduronide (free acid), 4-methylumbelliferyl iduronide, 4-methyl-2-oxo-2h-chromen-7-yl-alpha-l-idopyranosiduronic acid |
| PD044298 |
| CS-0185906 |
| HY-W127708 |
| 4-methylumbelliferyl-??-l-iduronide (free acid) |
| AKOS040755221 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (50.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.33
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.33) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (11.11%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (88.89%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||